The Cholinergic Hypothesis of Age and Alzheimer's Disease-Related Cognitive Deficits: Recent Challenges and Their Implications for Novel Drug Development-Reference-Cited by-同舟云学术

The Cholinergic Hypothesis of Age and Alzheimer's Disease-Related Cognitive Deficits: Recent Challenges and Their Implications for Novel Drug Development

Published:2003-06-12 Issue:3 Volume:306 Page:821-827
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Terry A. V.,Buccafusco J. J.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference65 articles.

1. Beta-amyloid induced increase in choline flux across PC12 cell membranes

2. Impairment of cholinergic neurotransmission in adult and aged transgenic Tg2576 mouse brain expressing the Swedish mutation of human β-amyloid precursor protein

3. Alzheimer’s disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies

4. On Neurodegenerative Diseases, Models, and Treatment Strategies: Lessons Learned and Lessons Forgotten a Generation Following the Cholinergic Hypothesis

Cited by 939 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring New 5‐Nitroimidazole Derivatives As Potent Acetylcholinesterase and Butyrylcholinesterase Enzyme Inhibitors;Chemistry & Biodiversity;2024-09-13

2. Microvascular and cellular dysfunctions in Alzheimer’s disease: an integrative analysis perspective;Scientific Reports;2024-09-09

3. Assessing indole derivative molecules as dual acetylcholinesterase and butyrylcholinesterase inhibitors through In Vitro inhibition and molecular modelling studies;Journal of Molecular Structure;2024-09

4. Evolving significance of kinase inhibitors in the management of Alzheimer's disease;European Journal of Pharmacology;2024-09

5. A review on synthetic inhibitors of dual-specific tyrosine phosphorylation-regulated kinase 1A (DYRK1A) for the treatment of Alzheimer’s disease (AD);Bioorganic & Medicinal Chemistry;2024-09